Associated tags: Biology, Patient, Spinal muscular atrophy, Transforming growth factor beta, Neuromuscular disease, SMA, Cancer, Rock, Gongshi, Biotechnology, Pharmaceutical, Health, Pharmaceutical industry, Webcast, Clinical Trials, Research, Clinical trial, Myostatin, SAPPHIRE, DRAGON, SMN, Neurology, Oncology, MPH, PIN
Locations: GILEAD, EUROPE, FL, UNITED STATES, NORTH AMERICA, MASSACHUSETTS
The company also announced that it granted inducement equity awards on January 19, 2024, covering an aggregate of 87,500 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 50,000 shares of common stock and inducement restricted stock units, covering an aggregate of 37,500 shares of its common stock.
Key Points:
- The company also announced that it granted inducement equity awards on January 19, 2024, covering an aggregate of 87,500 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 50,000 shares of common stock and inducement restricted stock units, covering an aggregate of 37,500 shares of its common stock.
- The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
- Vesting for the inducement restricted stock units will be in four equal annual installments.
- All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.
Retrieved on:
Thursday, January 4, 2024
Research,
Neurology,
Diabetes,
Clinical Trials,
Cardiology,
Biotechnology,
Managed Care,
Pharmaceutical,
Health,
Science,
Conference,
Cure,
IND,
SAPPHIRE,
Spinal muscular atrophy,
Clinical trial,
Obesity,
Standard of care,
Annual general meeting,
Gongshi,
Consequence,
Myostatin,
DRAGON,
Webcast,
MPH,
Patient,
Rock,
SMN,
SMA,
Renal cell carcinoma,
SITC,
Pharmaceutical industry Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
Key Points:
- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
- Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
- Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
- A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
Retrieved on:
Tuesday, November 7, 2023
Science,
Cardiology,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Gongshi,
Myostatin,
SMN,
SAPPHIRE,
IND,
PIN,
MPH,
Obesity,
Pembrolizumab,
Maintenance,
SITC,
Rock,
DRAGON,
Clinical trial,
Neoplasm,
Webcast,
Annual general meeting,
ORR,
Renal cell carcinoma,
SMA,
Patient,
Pharmaceutical industry,
Cryptocurrency The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.
Key Points:
- The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.
- Research and development expense was $30.3 million for the quarter ended September 30, 2023, compared to $33.4 million for the quarter ended September 30, 2022.
- General and administrative expense was $13.3 million for the quarter ended September 30, 2023, compared to $10.5 million for the quarter ended September 30, 2022.
- A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m.
Key Points:
- Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m.
- To access the conference call by phone, participants may register here to receive the dial-in number and unique PIN.
- A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
- An archived replay of the webcast will be available for approximately 90 days following the call.
Health,
Neurology,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
SMA,
Gongshi,
Pediatrics,
COVID-19,
Publication,
Johns Hopkins University,
Patient,
Standard of care,
Common,
Webcast,
Upper respiratory tract infection,
Headache,
Poster,
ADA,
Fatigue,
Pharmaceutical industry,
Nursing,
Amusement park,
Fever Improvement in Patient-Reported Outcomes Consistent with Improvements in Motor Function: Nonambulatory patients (ages 2-21) had improvements in PEDI-CAT (measure of activities of daily living) and PROMIS-Fatigue (a patient-reported outcome tool measuring fatigue) that were consistent and sustained at 36 months.
Key Points:
- Improvement in Patient-Reported Outcomes Consistent with Improvements in Motor Function: Nonambulatory patients (ages 2-21) had improvements in PEDI-CAT (measure of activities of daily living) and PROMIS-Fatigue (a patient-reported outcome tool measuring fatigue) that were consistent and sustained at 36 months.
- The mean change in PROMIS-Fatigue from baseline at 36 months was –4.6 (95% CI: –8.7, –0.5; N=14), indicating a decline in fatigue.
- These improvements in PEDI-CAT and PROMIS-Fatigue were generally consistent with improvements in motor function across the 36 months of the study period.
- More than 90 percent of nonambulatory patients remained on treatment in the extension study.
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
SMA,
Gongshi,
Myostatin,
ESMO,
Clinical trial,
SAPPHIRE,
Cure,
Part,
Net,
Congress,
Rock,
Patient,
Episcopal conference,
European Society of Gynaecological Oncology,
Research,
MDA,
Conference,
DRAGON,
Pharmaceutical industry,
Management,
Cryptocurrency Revenue was $0 for the quarter ended March 31, 2023, compared to $33.2 million for the quarter ended March 31, 2022.
Key Points:
- Revenue was $0 for the quarter ended March 31, 2023, compared to $33.2 million for the quarter ended March 31, 2022.
- Research and development expense was $29.7 million for the quarter ended March 31, 2023, compared to $29.4 million for the quarter ended March 31, 2022.
- General and administrative expense was $10.8 million for the quarter ended March 31, 2023, compared to $10.8 million for the quarter ended March 31, 2022.
- “Scholar Rock is in a strong financial position, and we are relentlessly focused on achieving our goal of improving the lives of patients who may potentially benefit from our medicines,” said Ted Myles, Chief Operating Officer and Chief Financial Officer of Scholar Rock.
